Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR2A | P27037 | 1/20 | 0.65 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.65 |
| ▸ | NAMPT | P43490 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412125 | 0.88 | ACVR2A (0.70) | ACVR2ATGFBR2NAMPTALDH1A1POLB | |
| SCHEMBL411189 | 0.86 | ACVR2A (0.79) | ACVR2ATGFBR2NAMPTALDH1A1KDM4E | |
| SCHEMBL408097 | 0.83 | ACVR2A (0.70) | ACVR2ATGFBR2NAMPT | |
| SCHEMBL413792 | 0.82 | ACVR2A (0.70) | ACVR2ATGFBR2ALDH1A1KDM4EHPGD | |
| SCHEMBL414392 | 0.82 | ACVR2A (0.76) | ACVR2ATGFBR2NAMPTALDH1A1KDM4E | |
| SCHEMBL415263 | 0.82 | ACVR2A (0.63) | ACVR2ATGFBR2NAMPTALDH1A1SLC1A5 | |
| SCHEMBL414317 | 0.82 | ACVR2A (0.62) | ACVR2ATGFBR2NAMPTMAPK1KDM4E | |
| SCHEMBL410490 | 0.81 | ACVR2A (0.69) | ACVR2ATGFBR2NAMPTMAPK1ALDH1A1 | |
| SCHEMBL410503 | 0.81 | ACVR2A (0.68) | ACVR2ATGFBR2NAMPTMAPK1KMT2A | |
| SCHEMBL447681 | 0.80 | ACVR2A (0.78) | ACVR2ATGFBR2NAMPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590347-A1 | ISOTHIAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| WO-2004067530-A1 | ISOTHIAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-08-12 | — | — | WO | claimed |
| US-20040147574-A1 | Isothiazole derivatives | PFIZER INC | 2004-07-29 | — | — | US | claimed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| EP-1590347-A1 | ISOTHIAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067530-A1 | ISOTHIAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20040147574-A1 | Isothiazole derivatives | PFIZER INC | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147574-A1 | Isothiazole derivatives | SMAD3, SMAD2, TGFBR1 | ACVR2A 85/4885TGFBR2 4/4885NAMPT 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.